Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Diagnostics › Molecular Diagnostics › Almac Dx Develops Prostate Cancer Assay to Detect Risk of Metastatic Recurrence

Almac Dx Develops Prostate Cancer Assay to Detect Risk of Metastatic Recurrence

Apr 25, 2017
|
Justin Petrone
Premium

NEW YORK (GenomeWeb) – Almac Diagnostics has developed a new test that can be used to identify prostate cancer patients at high risk of metastatic recurrence following treatment. The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.

Get the full story with
360Dx Premium

Only $95 for the
first 90 days*

360Dx Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try 360Dx Premium now.

You may already have institutional access!

Check if I qualify.

Already a 360Dx or GenomeWeb Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.
Apr
29
Featured Webinar

A New Generation of PCR: At-home Testing and Preparing for Emerging Strains of COVID-19

Sponsored by
Co-Diagnostics

Join Dr. Heather Fehling, Chief Scientific Officer at Clinical Reference Labs (CRL), as she provides some insights regarding the future applications of PCR testing.

May
13
Featured Webinar

Limits of Detection Matter: New Challenges for SARS-CoV-2 Diagnostics and COVID-19 Patient Management

Sponsored by
LGC SeraCare Life Sciences

As we pass the one-year anniversary of both the COVID-19 pandemic and the first Emergency Use Authorized SARS-CoV-2 PCR detection assays, there remains significant opportunity for clinical laboratories to advance testing and support improved patient management.

May
18
Featured Webinar

Put Your Money Where Your Mouth Is: Tracking and Attacking COVID-19 through State-Wide Saliva Surveillance

Sponsored by
Bio-Rad

This webinar will present the details of a COVID-19 saliva screening program that has been implemented at more than 90 different colleges, universities, private schools, and nursing homes across New York state.  

What's Popular?

In Molecular Diagnostics

  1. NIH Funds $33M in COVID-19 Testing Projects for Safe Return of Students, Staff to School

  2. Scope Fluidics Gets CE Mark for Rapid MRSA MDx Panel

  3. With Luminex Acquisition, DiaSorin to Broaden MDx Portfolio, Expand US Presence

    Premium

  4. Grail Cancer Early Detection Test Performance Holds Steady as Q2 Launch Approaches

    Premium

  5. Color Health, Yale Get FDA Emergency Use Authorization for Coronavirus Sample Collection Kits

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.